Vitae Pharmaceuticals (VTAE) Reports In-Line Q2 EPS

Vitae Pharmaceuticals (NASDAQ: VTAE) reported Q2 EPS of ($0.45), in-line with the analyst estimate of ($0.45). Revenue for the quarter came in at $161.6 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.

You May Also Be Interested In

• Netflix climbs following Ackman stake, up 1.8%
• Fermi Inc. (FRMI) Reports Q2 Loss of $0.04
• Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance